ANZCTR search results

Patient on Haemodialysis need Enoxaparin, a drug which is used to prevent blood clotting when the blood goes through the dialysis machine. The manufacturers recommendation is to give enoxaparin through the arterial route of the dialysis circuit. About 80% of enoxaparin gets eliminated by dialysis when administered through the arterial route of the circuit. Our hypothesis is that by administering enoxaparin via the venous route we will not lose the 80% of the drug and hence use less amount of enoxaparin.

This study looks at the effectiveness and safety of a single dose of PAT-SM6 in treating people with melanoma of the skin. Who is it for? You may be able to join this study if you have locally recurring cutaneous (skin) melanoma. You must not have received chemotherapy or therapeutic radiotherapy in the previous 28 days. You will be required to have a biopsy sample of the melanoma prior to receiving study medication. Trial details: Participants will all receive a single dose of human anti-GRP78 IgM monoclonal antibody PAT-SM6 via intravenous infusion over 60 minutes, at varying doses. They will return to the site on day 4 for another biopsy of the melanoma/surgery. Patients will remain on study for 5 weeks. The study aims to monitor the safety and effectiveness of treatment. What is PAT-SM6? PAT-SM6 is different to other antibodies on the market for cancer because it a naturally-occurring human molecule. It fights tumours by fixing on to specific targets on cancerous cells and killing them.

This study looks at whether the addition of adjuvant chemotherapy to standard cisplatin-based chemoradiation improves outcomes in women with locally advanced cervical cancer. Who is it for? You can join this study if you have locally advanced cervical cancer which is suitable for primary treatment with chemoradiation and you have not received any previous pelvic radiotherapy. Trial details: Participants will be divided into two groups. Both groups will be treated with standard external beam radiation treatment to the pelvis and brachytherapy(internal radiotherapy). They will receive cisplatin intravenously during the radiation at a dose of 40mg/m2 weekly for 5 doses. One group will also receive 4 cycles of 3 weekly adjuvant chemotherapy using carboplatin and paclitaxel intravenously, beginning within 4 weeks of completion of all radiation treatment. The study aims to see whether the adjuvant chemotherapy increases the response to treatment and improves survival times.

This study aims to determine whether hyperopic orthokeratology lenses can be used to provide effective mono-vision type correction for near vision in presbyopic adults. The effect of overnight hyperopic orthokeratology lens wear on refraction, ocular aberrations and corneal shape will also be investigated.

This project aims to chart the wellbeing of spouses/partners of Victorian aged care residents and secondly, to investigate the effectiveness of a support and discussion group in fostering the wellbeing of spouses/partners of aged care residents. The primary measures of wellbeing are depression, anxiety and burden. It is expected that spouses/partners in either immediate or delayed treatment groups will report similar benefit following intervention.

This study is aimed at evaluating a multifocal communication intervention incorporating a nurse-led patient and carer communication support program and and oncologist consultation skills training program. The intervention is intended to improve communication about life expectancy and end of life issues between patients with advanced incurable cancer, their carers and their oncologists in the final year of life.

There is limited published literature about the effectiveness of protocol initiated discharge in short-stay post-surgical units. The current study enrolled 182 participants who were randomly allocated to intervention or control groups.

The primary objectives of the study are to assess the safety, tolerability and pharmacokinetics of intact prodrug, PF329, as well as the pharmacokinetics of its pharmaceutically active form, hydromorphone, following increasing doses of a single oral administration of PF329 in healthy adult subjects

This pilot study looks at the effectiveness of acupuncture to reduce fatigue in women after treatment for breast cancer. You can join this study if you have recently been treated for breast cancer with chemotherapy, and you are suffering from fatigue associated with this treatment. Participants will be divided into three groups: an acupuncture treatment group, a placebo acupuncture group and a wait-list control group. Both the acupuncture and the placebo acupuncture groups will receive a type of acupuncture twice weekly over the first three weeks and then weekly for the final three weeks, with each treatment lasting 45 minutes. The placebo group will use a device which has a guide tube making it impossible for the subject to see whether the needle has penetrated the skin or not. Needle penetration does not occur. The sham needle will be placed away from acupuncture points. The wait list control group will receive no treatment for 6 weeks but will answer questionnaires during this time and be offered acupuncture treatment at the end of the 6 week study period. From 25% to 99% of people receiving cancer treatment suffer from fatigue. Preliminary reports suggest that acupuncture may help improve quality of life. The results of this study will be used in the design of a larger trial on the use of acupuncture to support cancer care.

People with newly diagnosed obstructive sleep apnoea for treatment with continuous positive airway pressure through a nasal mask (cPAP) are assigned to use a new custom fitted mask or the best-fit commercially available standard mask. There are 6 planned study visits over the 12 month treatment period. Participants are asked to complete study questionnaires at each study visit.